On January 27, 2026, the U.S. Department of Health and Human Services (“HHS”) Office of the Inspector General (“OIG”) issued a Special Advisory Bulletin (the “Bulletin”) detailing how the federal Anti-Kickback Statute (“AKS”) applies to direct-to-consumer (“DTC”) prescription drug sales by manufacturers to cash-paying patients enrolled in federal health care programs. The Bulletin provides... READ MORE
Selling Prescription Drugs Directly to Patients? OIG Flags Anti-Kickback Pitfalls with TrumpRx and Other DTC Programs
Posted on February 13, 2026 in Health Law News
Published by: Hall Render
